Results 51 to 60 of about 4,502 (185)
Addiction, EarlyView.Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock +8 more
wiley +1 more source
Journal of Experimental & Clinical Cancer Research, 2021 Background Castration-resistant prostate cancer (CRPC) is associated with a very poor prognosis, and the treatment of which remains a serious clinical challenge.
Shangwei Zhong +7 more
doaj +1 more source
Addiction, EarlyView.Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden +10 more
wiley +1 more source
Updated View on the Relation of the Pineal Gland to Autism Spectrum Disorders
Frontiers in Endocrinology, 2019 Identification of the biological features of autism is essential for designing an efficient treatment and for prevention of the disorder. Though the subject of extensive research, the neurophysiological features of autism remain unclear.
Tal Shomrat, Nir Nesher
doaj +1 more source
Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens [PDF]
, 2016 The present study investigated interactions between the novel psychoactive tryptamines DiPT, 4-OH-DiPT, 4-OH-MET, 5-MeO-AMT, and 5-MeO-MiPT at monoamine receptors and transporters compared with the classic hallucinogens lysergic acid diethylamide (LSD ...
Hoener, Marius C. +3 more
core +1 more source
Safety pharmacology of acute mescaline administration in healthy participants
British Journal of Clinical Pharmacology, EarlyView.Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber +4 more
wiley +1 more source
DMT alters cortical travelling waves
eLife, 2020 Psychedelic drugs are potent modulators of conscious states and therefore powerful tools for investigating their neurobiology. N,N, Dimethyltryptamine (DMT) can rapidly induce an extremely immersive state of consciousness characterized by vivid and ...
Andrea Alamia +4 more
doaj +1 more source
Psychedelics: A new era of treatment?
European Psychiatry, 2021 Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations.
S. Torres
doaj +1 more source
N, N-Dimethyltryptamine and Biological Reductive Accounts for Religious and Spiritual Experiences [PDF]
, 2014 There is unquestionably a plethora of details and mysteries regarding the mind and the body. However, with the advent of psychopharmacology (the study of how psychedelics inform or alter brain states), there are more issues at hand. Do psychedelics allow
Smith, Shaun
core +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source